HNSCC research hub

Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy

This study looks at combining special cancer drugs (PD-1/PD-L1 inhibitors) with radiation. It aims to see how well this works for various cancers and if we can find new ways to predict who will benefit most from this treatment.